1
|
Bravi CA, Dell’Oglio P, Pecoraro A, Khene ZE, Campi R, Diana P, Re C, Giulioni C, Tuna Beksac A, Bertolo R, Ajami T, Okhawere K, Meagher M, Alimohammadi A, Borghesi M, Mari A, Amparore D, Roscigno M, Anceschi U, Simone G, Suardi N, Galfano A, Schiavina R, Dehò F, Bensalah K, Erdem Canda A, Ferrara V, Alcaraz A, Zhang X, Terrone C, Shariat S, Porpiglia F, Antonelli A, Kaouk J, Badani K, Minervini A, Derweesh I, Breda A, Mottrie A, Montorsi F, Larcher A. Surgical Experience and Functional Outcomes after Laparoscopic and Robot-Assisted Partial Nephrectomy: Results from a Multi-Institutional Collaboration. J Clin Med 2024; 13:6016. [PMID: 39408076 PMCID: PMC11477761 DOI: 10.3390/jcm13196016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/12/2024] [Revised: 07/31/2024] [Accepted: 10/02/2024] [Indexed: 10/20/2024] Open
Abstract
Background: In patients treated with partial nephrectomy, prior evidence showed that peri-operative outcomes, such as complications and ischemia time, improved as a function of the surgical experience of the surgeon, but data on functional outcomes after surgery are still scarce. Methods: We retrospectively analyzed data of 4011 patients with a single, unilateral cT1a-b renal mass treated with laparoscopic or robot-assisted partial nephrectomy. The operations were performed by 119 surgeons at 22 participating institutions between 1997 and 2022. Multivariable models investigated the association between surgical experience (number of prior operations) and acute kidney injury (AKI) and recovery of at least 90% of baseline estimated glomerular filtration rate (eGFR) 1 yr after partial nephrectomy. The adjustment for case mix included age, Body Mass Index, preoperative serum creatinine, clinical T stage, PADUA score, warm ischemia time, pathologic tumor size, and year of surgery. Results: A total of 753 (19%) and 3258 (81%) patients underwent laparoscopic and robot-assisted partial nephrectomy, respectively. Overall, 37 (31%) and 55 (46%) surgeons contributed only to laparoscopic and robotic learning curves, respectively, whereas 27 (23%) contributed to the learning curves of both approaches. In the laparoscopic group, 8% and 55% of patients developed AKI and recovered at least 90% of their baseline eGFR, respectively. After adjusting for confounders, we did not find evidence of an association between surgical experience and AKI after laparoscopic partial nephrectomy (odds ratio [OR]: 0.9992; 95% confidence interval [CI]: 0.9963, 1.0022; p = 0.6). Similar results were found when 1-year renal function was the outcome of interest (OR: 0.9996; 95% CI: 0.9988, 1.0005; p = 0.5). Among patients who underwent robot-assisted partial nephrectomy, AKI occurred in 11% of patients, whereas 54% recovered at least 90% of their baseline eGFR. On multivariable analyses, the relationship between surgical experience and AKI after surgery was not statistically significant (OR: 1.0015; 95% CI: 0.9992, 1.0037; p = 0.2), with similar results when the outcome of interest was renal function one year after surgery (OR: 1.0001; 95% CI: 0.9980, 1.0022; p = 0.9). Virtually the same findings were found on sensitivity analyses. Conclusions: In patients treated with laparoscopic or robot-assisted partial nephrectomy, our data suggest that the surgical experience of the operating surgeon might not be a key determinant of functional recovery after surgery. This raises questions about the use of serum markers to assess functional recovery in patients with two kidneys and opens the discussion on what are the key steps of the procedure that allowed surgeons to achieve optimal outcomes since their initial cases.
Collapse
Affiliation(s)
- Carlo Andrea Bravi
- Department of Urology, The Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK
- Department of Urology, Onze-Lieve-Vrouwziekenhuis Hospital, 9300 Aalst, Belgium;
- ORSI Academy, 9090 Ghent, Belgium
- Unit of Urology, Division of Oncology, URI, IRCCS Ospedale San Raffaele, 20132 Milan, Italy; (C.R.); (F.M.); (A.L.)
| | - Paolo Dell’Oglio
- Department of Urology, ASST Grande Ospedale Metropolitano Niguarda, 20162 Milan, Italy; (P.D.); (A.G.)
- Department of Urology, Antoni van Leeuwenhoek Hospital, The Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands
- Interventional Molecular Imaging Laboratory, Department of Radiology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands
| | - Angela Pecoraro
- Department of Urology, Hospital Pederzoli, Peschiera del Garda, 37019 Verona, Italy
| | - Zine-Eddine Khene
- Department of Urology, University of Rennes, 35700 Rennes, France; (Z.-E.K.); (K.B.)
| | - Riccardo Campi
- Unit of Urological Robotic Surgery and Renal Transplantation, Department of Experimental and Clinical Medicine, Careggi Hospital, University of Florence, 50134 Florence, Italy;
| | - Pietro Diana
- Department of Urology, Fundació Puigvert, Autonoma University of Barcelona, 08025 Barcelona, Spain; (P.D.); (A.B.)
| | - Chiara Re
- Unit of Urology, Division of Oncology, URI, IRCCS Ospedale San Raffaele, 20132 Milan, Italy; (C.R.); (F.M.); (A.L.)
- ASST-Sette Laghi, Circolo & Fondazione Macchi Hospital, University of Insubria, 21100 Varese, Italy;
| | - Carlo Giulioni
- Unit of Urology, Jesi Hospital, Jesi, 60035 Ancona, Italy; (C.G.); (V.F.)
- Department of Urology, Polytechnic University of Marche Region, 60121 Ancona, Italy
| | - Alp Tuna Beksac
- Glickman Urological & Kidney Institute, Cleveland Clinic, Cleveland, OH 44106, USA; (A.T.B.); (J.K.)
| | - Riccardo Bertolo
- Department of Urology, San Carlo Di Nancy Hospital, 00165 Rome, Italy;
| | - Tarek Ajami
- Department of Urology, Hospital Clinic-IDIBAPS, University of Barcelona, 08036 Barcelona, Spain; (T.A.); (A.A.)
| | - Kennedy Okhawere
- Department of Urology, Icahn School of Medicine at Mount Sinai, New York City, NY 10029, USA; (K.O.); (K.B.)
| | - Margaret Meagher
- Department of Urology, University of California, La Jolla, San Diego, CA 92103, USA; (M.M.); (I.D.)
| | - Arman Alimohammadi
- Department of Urology, Medical University of Vienna, 1090 Vienna, Austria; (A.A.); (S.S.)
| | - Marco Borghesi
- Department of Surgical and Diagnostic Integrated Sciences (DISC), University of Genova, 16132 Genova, Italy; (M.B.); (C.T.)
| | - Andrea Mari
- Unit of Oncologic Minimally-Invasive Urology and Andrology—Careggi Hospital, Department of Clinical and Experimental Medicine, University of Florence, 50134 Florence, Italy; (A.M.); (A.M.)
| | - Daniele Amparore
- Department of Oncology, Division of Urology, University of Turin, San Luigi Gonzaga Hospital, Orbassano, 10043 Turin, Italy; (D.A.); (F.P.)
| | - Marco Roscigno
- ASST Papa Giovanni XXIII, 24125 Bergamo, Italy;
- School of Medicine, University of Milano-Bicocca, 20132 Milan, Italy
| | - Umberto Anceschi
- Department of Urology, IRCCS “Regina Elena” National Cancer Institute, 00128 Rome, Italy; (U.A.); (G.S.)
| | - Giuseppe Simone
- Department of Urology, IRCCS “Regina Elena” National Cancer Institute, 00128 Rome, Italy; (U.A.); (G.S.)
| | - Nazareno Suardi
- Department of Urology, University of Brescia, 25123 Brescia, Italy;
| | - Antonio Galfano
- Department of Urology, ASST Grande Ospedale Metropolitano Niguarda, 20162 Milan, Italy; (P.D.); (A.G.)
| | - Riccardo Schiavina
- Division of Urology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy;
| | - Federico Dehò
- ASST-Sette Laghi, Circolo & Fondazione Macchi Hospital, University of Insubria, 21100 Varese, Italy;
| | - Karim Bensalah
- Department of Urology, University of Rennes, 35700 Rennes, France; (Z.-E.K.); (K.B.)
| | - Abdullah Erdem Canda
- Department of Urology, Koç University Hospital, Istanbul 34010, Turkey;
- RMK AIMES, Rahmi M. Koç Academy of Interventional Medicine, Education, and Simulation, Istanbul 34010, Turkey
| | - Vincenzo Ferrara
- Unit of Urology, Jesi Hospital, Jesi, 60035 Ancona, Italy; (C.G.); (V.F.)
| | - Antonio Alcaraz
- Department of Urology, Hospital Clinic-IDIBAPS, University of Barcelona, 08036 Barcelona, Spain; (T.A.); (A.A.)
| | - Xu Zhang
- Department of Urology, Chinese PLA General Hospital, Beijing 100091, China;
| | - Carlo Terrone
- Department of Surgical and Diagnostic Integrated Sciences (DISC), University of Genova, 16132 Genova, Italy; (M.B.); (C.T.)
| | - Shahrokh Shariat
- Department of Urology, Medical University of Vienna, 1090 Vienna, Austria; (A.A.); (S.S.)
- Institute for Urology and Reproductive Health, Sechenov University, 119435 Moscow, Russia
| | - Francesco Porpiglia
- Department of Oncology, Division of Urology, University of Turin, San Luigi Gonzaga Hospital, Orbassano, 10043 Turin, Italy; (D.A.); (F.P.)
| | - Alessandro Antonelli
- Department of Urology, Azienda Ospedaliera Universitaria Integrata, University of Verona, 37126 Verona, Italy;
| | - Jihad Kaouk
- Glickman Urological & Kidney Institute, Cleveland Clinic, Cleveland, OH 44106, USA; (A.T.B.); (J.K.)
| | - Ketan Badani
- Department of Urology, Icahn School of Medicine at Mount Sinai, New York City, NY 10029, USA; (K.O.); (K.B.)
| | - Andrea Minervini
- Unit of Oncologic Minimally-Invasive Urology and Andrology—Careggi Hospital, Department of Clinical and Experimental Medicine, University of Florence, 50134 Florence, Italy; (A.M.); (A.M.)
| | - Ithaar Derweesh
- Department of Urology, University of California, La Jolla, San Diego, CA 92103, USA; (M.M.); (I.D.)
| | - Alberto Breda
- Department of Urology, Fundació Puigvert, Autonoma University of Barcelona, 08025 Barcelona, Spain; (P.D.); (A.B.)
| | - Alexandre Mottrie
- Department of Urology, Onze-Lieve-Vrouwziekenhuis Hospital, 9300 Aalst, Belgium;
- ORSI Academy, 9090 Ghent, Belgium
| | - Francesco Montorsi
- Unit of Urology, Division of Oncology, URI, IRCCS Ospedale San Raffaele, 20132 Milan, Italy; (C.R.); (F.M.); (A.L.)
| | - Alessandro Larcher
- Unit of Urology, Division of Oncology, URI, IRCCS Ospedale San Raffaele, 20132 Milan, Italy; (C.R.); (F.M.); (A.L.)
| |
Collapse
|
2
|
Grosso AA, Di Maida F, Lambertini L, Cadenar A, Coco S, Ciaralli E, Salamone V, Vittori G, Tuccio A, Mari A, Minervini A. 3D virtual model for robot-assisted partial nephrectomy in highly-complex cases (PADUA ⩾ 10). Urologia 2024; 91:568-573. [PMID: 38770765 DOI: 10.1177/03915603241252905] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/22/2024]
Abstract
PURPOSE To compare two cohorts of patients submitted to robot-assisted partial nephrectomy (RAPN) for highly-complex renal masses (PADUA ⩾ 10) with versus without the use of 3DVMs. MATERIALS AND METHODS We screened a prospective consecutive cohort of 152 patients submitted to RAPN with 3DVM and 1264 patients submitted to RAPN without 3DVM between 2019 and 2022. Only PADUA ⩾ 10 cases were considered eligible for analysis. Propensity score matching (PSM) analysis was applied. Primary endpoint was to evaluate whereas RAPNs with 3DVM were superior in terms of functional outcomes at 12-month. Secondary outcomes were to compare perioperative and oncological outcomes. Multivariable logistic regression analyses (MVA) tested the associations of clinically significant eGFR drop and 3DVMs. Subgroups analysis was performed for PAUDA-risk categories. RESULTS Thirty seven patients for each group were analyzed after PSM. RAPN with 3DVM presented a higher rate of selective/no clamping procedure (32.5% vs 16.2%, p = 0.03) and a higher enucleation rate (43.2% vs 29.8%, p = 0.04). Twelve-month functional preservation performed better within 3DVM group in terms of creatinine serum level (median 1.2 [IQR 1.1-1.4] vs 1.6 [IQR 1.1-1.8], p = 0.03) and eGFR (median 64.6 [IQR 56.2-74.1] vs 52.3 [IQR 49.2-74.1], p = 0.03). MVA confirmed 3DVM as a protective factor for clinically significant eGFR drop in this subgroup of patients. CONCLUSIONS RAPN performed with the use of 3DVM assistance for PADUA ⩾ 10 cases resulted in lower incidence of global ischemia and higher rate of enucleations. The positive impact of such technology was found at 12-month follow-up.
Collapse
Affiliation(s)
- Antonio Andrea Grosso
- Department of Experimental and Clinical Medicine, University of Florence - Unit of Oncologic, Minimally-invasive Urology and Andrology, Careggi Hospital, Florence, Italy
| | - Fabrizio Di Maida
- Department of Experimental and Clinical Medicine, University of Florence - Unit of Oncologic, Minimally-invasive Urology and Andrology, Careggi Hospital, Florence, Italy
| | - Luca Lambertini
- Department of Experimental and Clinical Medicine, University of Florence - Unit of Oncologic, Minimally-invasive Urology and Andrology, Careggi Hospital, Florence, Italy
| | - Anna Cadenar
- Department of Experimental and Clinical Medicine, University of Florence - Unit of Oncologic, Minimally-invasive Urology and Andrology, Careggi Hospital, Florence, Italy
| | - Simone Coco
- Department of Experimental and Clinical Medicine, University of Florence - Unit of Oncologic, Minimally-invasive Urology and Andrology, Careggi Hospital, Florence, Italy
| | - Elena Ciaralli
- Department of Experimental and Clinical Medicine, University of Florence - Unit of Oncologic, Minimally-invasive Urology and Andrology, Careggi Hospital, Florence, Italy
| | - Vincenzo Salamone
- Department of Experimental and Clinical Medicine, University of Florence - Unit of Oncologic, Minimally-invasive Urology and Andrology, Careggi Hospital, Florence, Italy
| | - Gianni Vittori
- Department of Experimental and Clinical Medicine, University of Florence - Unit of Oncologic, Minimally-invasive Urology and Andrology, Careggi Hospital, Florence, Italy
| | - Agostino Tuccio
- Department of Experimental and Clinical Medicine, University of Florence - Unit of Oncologic, Minimally-invasive Urology and Andrology, Careggi Hospital, Florence, Italy
| | - Andrea Mari
- Department of Experimental and Clinical Medicine, University of Florence - Unit of Oncologic, Minimally-invasive Urology and Andrology, Careggi Hospital, Florence, Italy
| | - Andrea Minervini
- Department of Experimental and Clinical Medicine, University of Florence - Unit of Oncologic, Minimally-invasive Urology and Andrology, Careggi Hospital, Florence, Italy
| |
Collapse
|
3
|
Grosso AA, Di Maida F, Lambertini L, Cadenar A, Coco S, Ciaralli E, Salamone V, Vittori G, Tuccio A, Mari A, Ludovico GM, Minervini A. Three-dimensional virtual model for robot-assisted partial nephrectomy: a propensity-score matching analysis with a contemporary control group. World J Urol 2024; 42:338. [PMID: 38767673 PMCID: PMC11106151 DOI: 10.1007/s00345-024-05043-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/25/2024] [Accepted: 05/06/2024] [Indexed: 05/22/2024] Open
Abstract
PURPOSE To compare two cohorts of patients submitted to robot-assisted partial nephrectomy (RAPN) with vs without the use of three-dimensional virtual models (3DVMs). METHODS We screened a prospective consecutive cohort of 152 patients submitted to RAPN with 3DVM and 1264 patients submitted to RAPN without 3DVM between 2019 and 2022. Propensity score matching analysis (PSMA) was applied. Primary endpoint was to evaluate whereas RAPNs with 3DVM were superior in terms of functional outcomes at 12-month. Secondary endopoints were to compare perioperative and oncological outcomes. Multivariable logistic regression analyses (MVA) tested the associations of clinically significant eGFR drop and 3DVMs. Subgroups analysis was performed for PAUDA-risk categories. RESULTS 100 patients for each group were analyzed after PSMA. RAPN with 3DVM presented a higher rate of selective/no clamping procedure (32% vs 16%, p = 0.03) and a higher enucleation rate (40% vs 29%, p = 0.04). As concern to primary endopoint, 12-month functional preservation performed better within 3DVM group in terms of creatinine serum level (median 1.2 [IQR 1.1-1.4] vs 1.6 [IQR 1.1-1.8], p = 0.03) and eGFR (median 64.6 [IQR 56.2-74.1] vs 52.3 [IQR 49.2-74.1], p = 0.03). However, this result was confirmed only in the PADUA ≥ 10 renal masses. Regarding secondary endpoints, no significative difference emerged between the two cohorts. MVA confirmed 3DVM as a protective factor for clinically significant eGFR drop only in high-risk (PADUA ≥ 10) masses. CONCLUSIONS RAPN performed with the use of 3DVM assistance resulted in lower incidence of global ischemia and higher rate of enucleations. The positive impact of such technology was found at 12-month only in high-risk renal masses.
Collapse
Affiliation(s)
- Antonio Andrea Grosso
- Department of Experimental and Clinical Medicine, Minimally-Invasive Urology and Andrology, University of Florence-Unit of Oncologic, Careggi Hospital, San Luca Nuovo, 50134, Florence, Italy.
| | - Fabrizio Di Maida
- Department of Experimental and Clinical Medicine, Minimally-Invasive Urology and Andrology, University of Florence-Unit of Oncologic, Careggi Hospital, San Luca Nuovo, 50134, Florence, Italy
| | - Luca Lambertini
- Department of Experimental and Clinical Medicine, Minimally-Invasive Urology and Andrology, University of Florence-Unit of Oncologic, Careggi Hospital, San Luca Nuovo, 50134, Florence, Italy
| | - Anna Cadenar
- Department of Experimental and Clinical Medicine, Minimally-Invasive Urology and Andrology, University of Florence-Unit of Oncologic, Careggi Hospital, San Luca Nuovo, 50134, Florence, Italy
| | - Simone Coco
- Department of Experimental and Clinical Medicine, Minimally-Invasive Urology and Andrology, University of Florence-Unit of Oncologic, Careggi Hospital, San Luca Nuovo, 50134, Florence, Italy
| | - Elena Ciaralli
- Department of Experimental and Clinical Medicine, Minimally-Invasive Urology and Andrology, University of Florence-Unit of Oncologic, Careggi Hospital, San Luca Nuovo, 50134, Florence, Italy
| | - Vincenzo Salamone
- Department of Experimental and Clinical Medicine, Minimally-Invasive Urology and Andrology, University of Florence-Unit of Oncologic, Careggi Hospital, San Luca Nuovo, 50134, Florence, Italy
| | - Gianni Vittori
- Department of Experimental and Clinical Medicine, Minimally-Invasive Urology and Andrology, University of Florence-Unit of Oncologic, Careggi Hospital, San Luca Nuovo, 50134, Florence, Italy
| | - Agostino Tuccio
- Department of Experimental and Clinical Medicine, Minimally-Invasive Urology and Andrology, University of Florence-Unit of Oncologic, Careggi Hospital, San Luca Nuovo, 50134, Florence, Italy
| | - Andrea Mari
- Department of Experimental and Clinical Medicine, Minimally-Invasive Urology and Andrology, University of Florence-Unit of Oncologic, Careggi Hospital, San Luca Nuovo, 50134, Florence, Italy
| | | | - Andrea Minervini
- Department of Experimental and Clinical Medicine, Minimally-Invasive Urology and Andrology, University of Florence-Unit of Oncologic, Careggi Hospital, San Luca Nuovo, 50134, Florence, Italy
| |
Collapse
|
4
|
Bertolo R, Antonelli A, Minervini A, Campi R. Off-clamp Versus On-clamp Partial Nephrectomy: Re-envision of a Dilemma. Eur Urol Oncol 2024; 7:173-176. [PMID: 38245480 DOI: 10.1016/j.euo.2023.12.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/27/2023] [Accepted: 12/28/2023] [Indexed: 01/22/2024]
Abstract
We contextualize controversial evidence on the impact of warm ischemia on functional outcomes after partial nephrectomy for localized renal tumors and provide a holistic framework for re-envisioning the dilemma of off-clamp versus on-clamp surgery. The focus should shift away from the surgeon towards patient- and kidney-related characteristics.
Collapse
Affiliation(s)
- Riccardo Bertolo
- Department of Urology, Azienda Ospedaliera Universitaria Integrata, Borgo Trento Hospital, University of Verona, Verona, Italy.
| | - Alessandro Antonelli
- Department of Urology, Azienda Ospedaliera Universitaria Integrata, Borgo Trento Hospital, University of Verona, Verona, Italy
| | - Andrea Minervini
- Unit of Urological Oncologic Minimally Invasive Robotic Surgery and Andrology, Careggi Hospital, University of Florence, Florence, Italy; Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy
| | - Riccardo Campi
- Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy; Unit of Urological Robotic Surgery and Renal Transplantation, Careggi Hospital, University of Florence, Florence, Italy.
| |
Collapse
|
5
|
Campi R, Pecoraro A, Serni S, Minervini A. Robotic Versus Open Partial Nephrectomy: From the "Shadows" of Randomized Controlled Trials to the "Reality" of Value-based Care for Patients with Localized Renal Masses. Eur Urol Oncol 2024; 7:98-101. [PMID: 37438223 DOI: 10.1016/j.euo.2023.06.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/16/2023] [Accepted: 06/26/2023] [Indexed: 07/14/2023]
Affiliation(s)
- Riccardo Campi
- Unit of Urological Robotic Surgery and Renal Transplantation, University of Florence, Careggi Hospital, Florence, Italy; Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy; European Association of Urology Young Academic Urologists Renal Cancer Working Group, Arnhem, The Netherlands.
| | - Alessio Pecoraro
- Unit of Urological Robotic Surgery and Renal Transplantation, University of Florence, Careggi Hospital, Florence, Italy
| | - Sergio Serni
- Unit of Urological Robotic Surgery and Renal Transplantation, University of Florence, Careggi Hospital, Florence, Italy; Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy
| | - Andrea Minervini
- Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy; Unit of Urological Oncologic Minimally Invasive Robotic Surgery and Andrology, Careggi Hospital, University of Florence, Florence, Italy
| |
Collapse
|
6
|
Saitta C, Afari JA, Autorino R, Capitanio U, Porpiglia F, Amparore D, Piramide F, Cerrato C, Meagher MF, Noyes SL, Pandolfo SD, Buffi NM, Larcher A, Hakimi K, Nguyen MV, Puri D, Diana P, Fasulo V, Saita A, Lughezzani G, Casale P, Antonelli A, Montorsi F, Lane BR, Derweesh IH. Development of a novel score (RENSAFE) to determine probability of acute kidney injury and renal functional decline post surgery: A multicenter analysis. Urol Oncol 2023; 41:487.e15-487.e23. [PMID: 37880003 DOI: 10.1016/j.urolonc.2023.09.015] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2023] [Revised: 09/15/2023] [Accepted: 09/25/2023] [Indexed: 10/27/2023]
Abstract
OBJECTIVE To create and validate 2 models called RENSAFE (RENalSAFEty) to predict postoperative acute kidney injury (AKI) and development of chronic kidney disease (CKD) stage 3b in patients undergoing partial (PN) or radical nephrectomy (RN) for kidney cancer. METHODS Primary objective was to develop a predictive model for AKI (reduction >25% of preoperative eGFR) and de novo CKD≥3b (<45 ml/min/1.73m2), through stepwise logistic regression. Secondary outcomes include elucidation of the relationship between AKI and de novo CKD≥3a (<60 ml/min/1.73m2). Accuracy was tested with receiver operator characteristic area under the curve (AUC). RESULTS AKI occurred in 452/1,517 patients (29.8%) and CKD≥3b in 116/903 patients (12.8%). Logistic regression demonstrated male sex (OR = 1.3, P = 0.02), ASA score (OR = 1.3, P < 0.01), hypertension (OR = 1.6, P < 0.001), R.E.N.A.L. score (OR = 1.2, P < 0.001), preoperative eGFR<60 (OR = 1.8, P = 0.009), and RN (OR = 10.4, P < 0.0001) as predictors for AKI. Age (OR 1.0, P < 0.001), diabetes mellitus (OR 2.5, P < 0.001), preoperative eGFR <60 (OR 3.6, P < 0.001) and RN (OR 2.2, P < 0.01) were predictors for CKD≥3b. AUC for RENSAFE AKI was 0.80 and 0.76 for CKD≥3b. AKI was predictive for CKD≥3a (OR = 2.2, P < 0.001), but not CKD≥3b (P = 0.1). Using 21% threshold probability for AKI achieved sensitivity: 80.3%, specificity: 61.7% and negative predictive value (NPV): 88.1%. Using 8% cutoff for CKD≥3b achieved sensitivity: 75%, specificity: 65.7%, and NPV: 96%. CONCLUSION RENSAFE models utilizing perioperative variables that can predict AKI and CKD may help guide shared decision making. Impact of postsurgical AKI was limited to less severe CKD (eGFR<60 ml/min 71.73m2). Confirmatory studies are requisite.
Collapse
Affiliation(s)
- Cesare Saitta
- University of California: San Diego Health System, San Diego, CA; Department of Urology, IRCCS Humanitas Clinical and Research Hospital, Rozzano, Italy; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy
| | - Jonathan A Afari
- University of California: San Diego Health System, San Diego, CA
| | | | - Umberto Capitanio
- Department of Urology, San Raffaele Scientific Institute, Milan, Italy
| | - Francesco Porpiglia
- Department of Urology, San Luigi Gonzaga Hospital, University of Turin, Orbassano, Italy
| | - Daniele Amparore
- Department of Urology, San Luigi Gonzaga Hospital, University of Turin, Orbassano, Italy
| | - Federico Piramide
- Department of Urology, San Luigi Gonzaga Hospital, University of Turin, Orbassano, Italy
| | - Clara Cerrato
- University of California: San Diego Health System, San Diego, CA; Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy
| | | | - Sabrina L Noyes
- Spectrum Health, Grand Rapids, Michigan State University College of Human Medicine, Grand Rapids, MI
| | | | - Nicolò M Buffi
- Department of Urology, IRCCS Humanitas Clinical and Research Hospital, Rozzano, Italy; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy
| | | | - Kevin Hakimi
- University of California: San Diego Health System, San Diego, CA
| | - Mimi V Nguyen
- University of California: San Diego Health System, San Diego, CA
| | - Dhruv Puri
- University of California: San Diego Health System, San Diego, CA
| | - Pietro Diana
- Department of Urology, IRCCS Humanitas Clinical and Research Hospital, Rozzano, Italy; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy
| | - Vittorio Fasulo
- Department of Urology, IRCCS Humanitas Clinical and Research Hospital, Rozzano, Italy; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy
| | - Alberto Saita
- Department of Urology, IRCCS Humanitas Clinical and Research Hospital, Rozzano, Italy
| | - Giovanni Lughezzani
- Department of Urology, IRCCS Humanitas Clinical and Research Hospital, Rozzano, Italy; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy
| | - Paolo Casale
- Department of Urology, IRCCS Humanitas Clinical and Research Hospital, Rozzano, Italy
| | - Alessandro Antonelli
- Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy
| | | | - Brian R Lane
- Spectrum Health, Grand Rapids, Michigan State University College of Human Medicine, Grand Rapids, MI
| | | |
Collapse
|
7
|
Roussel E, Amparore D, Bertolo R, Pecoraro A, Campi R, Mottrie A. "Sutureless success:" can new devices make renorrhaphy after partial nephrectomy obsolete? Minerva Urol Nephrol 2023; 75:788-790. [PMID: 38126295 DOI: 10.23736/s2724-6051.23.05642-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2023]
Affiliation(s)
- Eduard Roussel
- Department of Urology, University Hospitals Leuven, Leuven, Belgium
- Department of Urology, OLV Hospital Aalst, Aalst, Belgium
| | - Daniele Amparore
- Department of Urology, San Luigi Gonzaga Hospital, University of Turin, Orbassano, Turin, Italy -
| | - Riccardo Bertolo
- Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata Verona, Verona, Italy
| | - Alessio Pecoraro
- Unit of Urological Robotic Surgery and Renal Transplantation, Careggi Hospital, University of Florence, Florence, Italy
| | - Riccardo Campi
- Unit of Urological Robotic Surgery and Renal Transplantation, Careggi Hospital, University of Florence, Florence, Italy
| | | |
Collapse
|